These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 33189118)
41. Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment. Mirra V; Montella S; Santamaria F BMC Pediatr; 2018 Feb; 18(1):73. PubMed ID: 29466963 [TBL] [Abstract][Full Text] [Related]
42. Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. Vijverberg SJ; Koster ES; Koenderman L; Arets HG; van der Ent CK; Postma DS; Koppelman GH; Raaijmakers JA; Maitland-van der Zee AH Pediatr Allergy Immunol; 2012 Sep; 23(6):529-36. PubMed ID: 22624949 [TBL] [Abstract][Full Text] [Related]
43. Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO). Turner S; Cotton SC; Emele CD; Thomas R; Fielding S; Gaillard EA; de Jongste JC; Morgan H; Neilson AR; Norrie J; Pijnenburg M; Price D; Thomas M Trials; 2019 Oct; 20(1):573. PubMed ID: 31585544 [TBL] [Abstract][Full Text] [Related]
44. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150 [TBL] [Abstract][Full Text] [Related]
45. Predictive value of lung function trend and FeNO for difficult asthma in children. Agache I; Ciobanu C J Investig Allergol Clin Immunol; 2012; 22(6):419-26. PubMed ID: 23101186 [TBL] [Abstract][Full Text] [Related]
46. Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study. Vijverberg SJ; Koenderman L; van Erp FC; van der Ent CK; Postma DS; Brinkman P; Sterk PJ; Raaijmakers JA; Maitland-van der Zee AH BMC Pediatr; 2013 Jun; 13():94. PubMed ID: 23768206 [TBL] [Abstract][Full Text] [Related]
47. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Trivedi A; Pavord ID; Castro M Lancet Respir Med; 2016 Jul; 4(7):585-592. PubMed ID: 27230825 [TBL] [Abstract][Full Text] [Related]
48. Biologics in the treatment of asthma in children and adolescents. Bacharier LB; Jackson DJ J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649 [TBL] [Abstract][Full Text] [Related]
50. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533 [TBL] [Abstract][Full Text] [Related]
51. Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice. Mahr TA; Malka J; Spahn JD Allergy Asthma Proc; 2013; 34(3):210-9. PubMed ID: 23462278 [TBL] [Abstract][Full Text] [Related]
52. Asthma diagnosis and severity monitoring in primary school children: essential role of sequential testing of exhaled nitric oxide. Wan KS; Chiu WH; Yang W Allergol Immunopathol (Madr); 2014; 42(5):439-43. PubMed ID: 23830305 [TBL] [Abstract][Full Text] [Related]
53. Asthma control in a random sample of New Zealand adolescent asthmatics. van Dalen CJ; Harding E; Parkin J; Blakey K; Cheng S; Pearce NE; Douwes J J Asthma; 2007 May; 44(4):261-6. PubMed ID: 17530523 [TBL] [Abstract][Full Text] [Related]
54. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972 [TBL] [Abstract][Full Text] [Related]
55. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Pike K; Selby A; Price S; Warner J; Connett G; Legg J; Lucas JS; Peters S; Buckley H; Magier K; Foote K; Drew K; Morris R; Lancaster N; Roberts G Clin Respir J; 2013 Apr; 7(2):204-13. PubMed ID: 22747899 [TBL] [Abstract][Full Text] [Related]
56. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma. Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394 [TBL] [Abstract][Full Text] [Related]
57. Risk factors hindering asthma symptom control in Saudi children and adolescents. Halwani R; Vazquez-Tello A; Horanieh N; Dulgom S; Al-Aseri Z; Al-Khamis N; Al-Sum Z; Al-Jahdali H; Al-Muhsen S Pediatr Int; 2017 Jun; 59(6):661-668. PubMed ID: 28218986 [TBL] [Abstract][Full Text] [Related]
58. Low-grade disease activity in early life precedes childhood asthma and allergy. Chawes BL Dan Med J; 2016 Aug; 63(8):. PubMed ID: 27477800 [TBL] [Abstract][Full Text] [Related]
59. Combining the Mannitol Test and FeNO in the Assessment of Poorly Controlled Asthma. Porsbjerg C; Sverrild A; Backer V J Allergy Clin Immunol Pract; 2015; 3(4):553-9. PubMed ID: 25824441 [TBL] [Abstract][Full Text] [Related]
60. Problematic severe asthma in children, not one problem but many: a GA2LEN initiative. Hedlin G; Bush A; Lødrup Carlsen K; Wennergren G; De Benedictis FM; Melén E; Paton J; Wilson N; Carlsen KH; Eur Respir J; 2010 Jul; 36(1):196-201. PubMed ID: 20595164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]